Two different “takes” from the results of the CHAARTED trial

In the October 15 issue of Oncology differing authors provide differing perspectives on the interpretation of the results of the CHAARTED trial reported by Sweeney et al. at the annual meeting of the American Society for Clinical Oncology earlier this year. … READ MORE …

Evolution of the mCRPC treatment landscape

A new article by Jeffress in the cancer business publication OBR Green discusses the changing patterns of use of  the various approved drugs in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

KPT-330 in treatment of mCRPC

Earlier this year, Karyopharm Therapeutics initiated a Phase II clinical trial of KPT-330 in treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who had progressed on treatment with drugs like abiraterone acetate and enzalutamide. … READ MORE …

“Final” data on abiraterone acetate in treatment of chemo-naive mCRPC

According to a media release issued on Sunday, the most recent “final” update to the COU-AA-302 trial has shown that treatment with abiraterone + prednisone provided a statistically significant overall survival benefit in the treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Data from early access trial of abiraterone acetate in post-chemo mCRPC

A new article in The Lancet Oncology has provided us with data from the early access trial of abiraterone acetate + predisone conducted in men with post-chemotherapy, metastatic, castration-resistant prostate cancer (mCRPC) in a total of 23 countries around the world. … READ MORE …

Tokai plans for Phase III trial of galeterone in 2015

Tokai Pharmaceuticals — a US-based biotechnology company — went public yesterday and was supposedly able to raise more than enough money to initiate a pivotal, Phase III, randomized clinical trial of its investigational drug galeterone (TOK-001) in treatment of late stage prostate cancer. … READ MORE …

FDA approves use of enzalutamide in chemotherapy-naive mCRPC

This afternoon the U.S. Food & Drug Administration approved enzalutamide (Xtandi) as a treatment for patients with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC) based on the results of the PREVAIL trial. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,153 other followers